X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
NRX-101 (D-cycloserine & Lurasidone HCl) shows no measurable damage to either intestinal or vaginal flora, compared to the significant negative effect caused by drugs, in rodent model having complicated urinary tract infections associated with pseudomembranous colitis and vaginal yeast infections.
Lead Product(s): Cycloserine,Lurasidone Hydrochloride
Therapeutic Area: Infections and Infectious Diseases Product Name: NRX-101
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 17, 2024
Details:
HTX-100 (ketamine) is an intravenous NMDA 3A receptor antagonist, which is currebntly being evaluated for the treatment of Bipolar Depression & Suicidal Ideation.
Lead Product(s): Ketamine Hydrochloride
Therapeutic Area: Psychiatry/Psychology Product Name: HTX-100
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 15, 2024
Details:
NRX-101 is a fixed dose combination of the NMDA antagonist D-cycloserine and lurasidone. It is being evaluated in phase 2/3 clinical trials for the treatment of treatment resistant bipolar depression & suicidal ideation.
Lead Product(s): Cycloserine,Lurasidone Hydrochloride
Therapeutic Area: Psychiatry/Psychology Product Name: NRX-101
Highest Development Status: Phase II/ Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 04, 2024
Details:
The net proceeds will be used in the development of NRX100 (ketamine hydrochloride), which is currently being evaluated in clinical trial studies for patients with Bipolar Depression and suicidal ideation.
Lead Product(s): Ketamine Hydrochloride
Therapeutic Area: Psychiatry/Psychology Product Name: NRX-100
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Undisclosed
Deal Size: $1.0 million Upfront Cash: $1.0 million
Deal Type: Agreement March 01, 2024
Details:
NRX-100 (IV Ketamine) is a NMDA 3A receptor inhibitor, which is being evaluated as a potentially lifesaving treatment option for patients with Suicidal Depression.
Lead Product(s): Ketamine Hydrochloride
Therapeutic Area: Psychiatry/Psychology Product Name: NRX-100
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 26, 2024
Details:
The collaborations aim to support NRx for the development of NRX-101 (D-cycloserine) in the treatment of bipolar depression with suicidality.
Lead Product(s): Cycloserine,Lurasidone Hydrochloride
Therapeutic Area: Psychiatry/Psychology Product Name: NRX-101
Highest Development Status: Phase II/ Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Alvogen
Deal Size: $345.0 million Upfront Cash: $10.0 million
Deal Type: Collaboration February 11, 2024
Details:
The incorporation of HOPE therapeutics will focus on the development of NRX-100 (IV Ketamine), which will be re-designated as HTX-100, a potentially lifesaving treatment option for patients with Suicidal Depression.
Lead Product(s): Ketamine Hydrochloride
Therapeutic Area: Psychiatry/Psychology Product Name: NRX-100
Highest Development Status: Phase IIIProduct Type: Small molecule
Recipient: HOPE Therapeutics
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Merger February 05, 2024
Details:
NRX-101 is a fixed dose combination of the NMDA antagonist D-cycloserine and lurasidone. It is being evaluated in phase 2/3 clinical trials for the treatment of treatment resistant bipolar depression & suicidal ideation.
Lead Product(s): Cycloserine,Lurasidone Hydrochloride
Therapeutic Area: Psychiatry/Psychology Product Name: NRX-101
Highest Development Status: Phase II/ Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 22, 2024
Details:
NRX-101 (a fixed dose combination of D-cycloserine (DCS) and lurasidone HCl (lurasidone)) is an active antibiotic ingredient, NMDA receptor modulator which is under phase 2 clinical development for the treatment of complicated urinary tract infection and pyelonephritis.
Lead Product(s): Cycloserine,Lurasidone Hydrochloride
Therapeutic Area: Infections and Infectious Diseases Product Name: NRX-101
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 16, 2024
Details:
Through the agreement, NRx will focus on the NRX-100 (ketamine HCl), NMDA 3A inhibitor. It is being evaluated in Phase III clinical trial studies with patients for the treatment of Bipolar Depression and related to Suicidal Ideation.
Lead Product(s): Ketamine Hydrochloride
Therapeutic Area: Psychiatry/Psychology Product Name: NRX-100
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Columbia University
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement December 19, 2023
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
